题目
题目

PCOL2021 2025 Practice MCQ Section A - 2025

单项选择题

Evaluate the implications of pharmacogenomic variations in metabolizing enzymes when designing a clinical trial for a new cardiovascular drug.

选项
A.It is necessary to standardize genetic backgrounds to avoid skewed data on drug efficacy.
B.Pharmacogenomic variations are irrelevant unless the trial involves genetic therapies.
C.Only the dosage of the drug should be adjusted without considering genetic variations.
D.Genetic variations should not influence the trial design as they are rarely significant.
查看解析

查看解析

标准答案
Please login to view
思路分析
When evaluating how pharmacogenomic variations in metabolizing enzymes affect clinical trial design for a cardiovascular drug, several plausible implications arise. Option 1: 'It is necessary to standardize genetic backgrounds to avoid skewed data on drug efficacy.' This statement captures a key methodological consideration: genetic differences in drug metabolism can influence ......Login to view full explanation

登录即可查看完整答案

我们收录了全球超50000道考试原题与详细解析,现在登录,立即获得答案。

类似问题

Mrs. Gupta is prescribed omeprazole, a proton pump inhibitor metabolized primarily by CYP2C19. Her pharmacogenomic report shows she is a CYP2C19 ultra-rapid metabolizer. Based on this genetic profile, what clinical outcomes should be anticipated, and how should her treatment be adjusted?[Fill in the blank]

How can genetic variation in HLA antigens influence drug therapy outcomes?

When considering the variability of drug metabolism among different geographical ancestries, which factor is most relevant for optimizing patient-specific therapy?

In evaluating a patient’s CYP2D6 phenotype before prescribing a drug with a narrow therapeutic window, which of the following represents the most critical clinical concerns?

更多留学生实用工具

加入我们，立即解锁 海量真题 与 独家解析，让复习快人一步！